Edgar Filing: ENDO PHARMA LLC - Form 4

ENDO PHA Form 4										
September 1:	_							OMB A	PPROVAL	
FORM	4 UNITED S					NGE C	COMMISSION	OMB	3235-0287	
Check thi			Washington,	, D.C. 20	549			Number: Expires:	January 31,	
if no long subject to Section 1 Form 4 o Form 5	6. r Filed purs	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,								
obligation may cont <i>See</i> Instru 1(b).	inue. Section 17(2	·	c Utility Hole e Investment	U			1935 or Section	n		
(Print or Type F	Responses)									
1. Name and Address of Reporting Person <u>*</u> ENDO PHARMA LLC			21 Issuel I tunie una Tiener of Trading				5. Relationship of Reporting Person(s) to Issuer			
							(Check all applicable)			
(Last) 320 PARK		(Mo	ate of Earliest Tr nth/Day/Year) 15/2005	ransaction			Director Difficer (give below)	title Otho below)		
	(Street)	4. If	Amendment, Da	ate Original			6. Individual or Jo	int/Group Filin	ng(Check	
NEW YORI	K, NY 10022	Fileo	l(Month/Day/Year	r)			Applicable Line) _X_ Form filed by C Form filed by M Person			
(City)	(State)	(Zip)	Table I - Non-I	Derivative S	Securi	ties Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3. e, if Transaction Code	3.4. Securities Acquired5. Amount ofTransaction(A) or Disposed of (D)SecuritiesCode(Instr. 3, 4 and 5)Beneficially			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of		
~			Code V	Amount	(D)	Price	(Instr. 3 and 4)			
Common Stock, par value \$.01 per share	09/15/2005		Х	24,000	D	\$ 2.42	63,288,284	D		
Common Stock, par value \$.01 per share	09/15/2005		X	99,000	D	\$ 3.42	63,189,284	D		
Common Stock, par value \$.01 per share	09/15/2005		Х	5,000	D	\$ 2.42	63,184,284	D		

Edgar Filing: ENDO PHARMA LLC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Call Option (obligation to sell)	\$ 2.42	09/15/2005		Х	24,000	10/01/2001	08/26/2007	Common Stock	24,000
Call Option (obligation to sell)	\$ 3.42	09/15/2005		Х	99,000	10/20/2001	08/26/2007	Common Stock	99,000
Call Option (obligation to sell)	\$ 2.42	09/15/2005		Х	5,000	11/29/2004	08/26/2007	Common Stock	5,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	•	Other			
ENDO PHARMA LLC							
320 PARK AVENUE		Х					
NEW YORK, NY 10022							
Signatures							
/s/ Jeffrey R. Black Chief Finan Officer	ncial	09/	15/2005				
**Signature of Reporting Person			Date				

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Edgar Filing: ENDO PHARMA LLC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.